Rohit Aggarwal
A5021312163- Inflammatory Myopathies and Dermatomyositis
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Muscle Physiology and Disorders
- SARS-CoV-2 and COVID-19 Research
- Skin Diseases and Diabetes
- Systemic Lupus Erythematosus Research
- Celiac Disease Research and Management
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Rheumatoid Arthritis Research and Therapies
- Peripheral Neuropathies and Disorders
- Autoimmune and Inflammatory Disorders Research
- Parkinson's Disease and Spinal Disorders
- Autoimmune Bullous Skin Diseases
- Muscle and Compartmental Disorders
- Chronic Lymphocytic Leukemia Research
- Viral Infections and Immunology Research
- COVID-19 Clinical Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Spondyloarthritis Studies and Treatments
- Dermatological and COVID-19 studies
- Neurogenetic and Muscular Disorders Research
- Dupuytren's Contracture and Treatments
University of Pittsburgh
2016-2025
University of Pittsburgh Medical Center
2014-2025
Public Works Department Buildings and Roads
2024
Post Graduate Institute of Medical Education and Research
2024
Southern Command Hospital
2021-2024
Central South University
2024
University of Miami
2024
Policlinico San Matteo Fondazione
2024
Gunma University
2024
Second Xiangya Hospital of Central South University
2024
<h3>Objective</h3> To develop and validate new classification criteria for adult juvenile idiopathic inflammatory myopathies (IIM) their major subgroups. <h3>Methods</h3> Candidate variables were assembled from published expert opinion using consensus methodology. Data collected 47 rheumatology, dermatology, neurology paediatric clinics worldwide. Several statistical methods used to derive the criteria. <h3>Results</h3> Based on data 976 IIM patients (74% adults; 26% children) 624 non-IIM...
To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial adult pediatric myositis patients.Adults with refractory polymyositis (PM) adults children dermatomyositis (DM) were enrolled. Entry criteria included muscle weakness ≥2 additional abnormal values on core set measures (CSMs) for adults. Juvenile DM patients required ≥3 CSMs, or without weakness. Patients randomized to receive either early late, glucocorticoid immunosuppressive therapy was...
To develop and validate new classification criteria for adult juvenile idiopathic inflammatory myopathies (IIM) their major subgroups.Candidate variables were assembled from published expert opinion using consensus methodology. Data collected 47 rheumatology, dermatology, neurology, pediatric clinics worldwide. Several statistical methods utilized to derive the criteria.Based on data 976 IIM patients (74% adults; 26% children) 624 non-IIM with mimicking conditions (82% 18% children),...
The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). aim Phase 2 development process was to achieve expert consensus on clinical laboratory variables that should contribute final set.Twenty-four RA clinicians (12 from Europe 12 North America) participated in 2. A consensus-based decision analysis approach used identify factors (and their relative weights) influence probability "developing...
To compare the cumulative survival and event free in patients with Jo-1 versus non-Jo-1 anti-tRNA synthetase autoantibodies (anti-synAb).Anti-synAb positive initially evaluated from 1985 to 2009 were included regardless of connective tissue disease (CTD) diagnosis. Clinical data extracted a prospectively collected database chart review. Survival between was compared by log rank Cox proportional hazards methods.202 possessed anti-synAb: 122 80 (35 PL-12; 25 PL-7; 9 EJ; 6 KS; 5 OJ). The...
Objective To identify the clinical and laboratory predictors of improvement in a cohort myositis patients treated with rituximab. Methods We analyzed data for 195 (75 adult polymyositis [PM], 72 dermatomyositis [DM], 48 juvenile DM) Rituximab Myositis trial. Clinical was defined as 20% at least 3 following 6 core set measures disease activity: physician's patient's/parent's global assessment activity, manual muscle testing, physical function, enzymes, extramuscular activity. association...
Clinically amyopathic dermatomyositis (CADM) is a subset of (DM) presenting with the characteristic rash DM without objective muscle weakness. Asian studies report that anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in CADM associated interstitial lung disease (ILD), particularly rapidly progressive ILD (RPILD). These associations have not been established US myositis patients. The goal our study was to determine association anti-MDA-5 ILD, RPILD, and survival...
Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.
We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).
Objective We provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, Sjögren disease. Methods developed clinically relevant population, intervention, comparator, outcomes questions related to patients SARDs. A systematic literature review was...
Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, available evidence rated using Grading Recommendations, Assessment, Development, Evaluation methodology. panel clinicians patients reached consensus on direction strength...
Objective To describe the methodology used to develop new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) their major subgroups. Methods An international, multidisciplinary group of myositis experts produced a set 93 potentially relevant variables be tested inclusion in criteria. Rheumatology, dermatology, neurology paediatric clinics worldwide collected data on 976 IIM cases (74% adults, 26% children) 624 non-IIM comparator with mimicking conditions...
Abstract Objective To describe the classification, demographic and clinical features, survival in anti–U3 RNP autoantibody–positive patients with systemic sclerosis (SSc). Methods Medical records of 108 RNP–positive 2,471 RNP–negative SSc first evaluated during 1985–2003 were reviewed. Anti–U3 antibody was detected by protein RNA immunoprecipitation. Disease organ system involvement, compared between 2 patient groups, Student's t ‐test, chi‐square analysis, Mantel‐Haenszel test. Results The...
To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either International Myositis Assessment and Clinical Studies Group (IMACS) or Paediatric Rheumatology Trials Organisation (PRINTO) were derived natural history data a conjoint analysis survey. They further validated using PRINTO trial prednisone alone compared to with methotrexate cyclosporine Rituximab in (RIM) trial. At consensus conference,...